Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug

Patent metadata

Field	Value
Publication number	US-10456464-B2
Application number	US-201515501339-A
Country	US
Kind code	B2
Filing date	Aug 4, 2015
Priority date	Aug 4, 2014
Publication date	Oct 29, 2019
Grant date	Oct 29, 2019

Abstract

The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.

First claim

The invention claimed is:

1. A vaccine pharmaceutical composition for inducing humoral immunity, comprising:
an infectious pathogen-derived antigen in an amount of 0.000001 to 50% by weight based on a total weight of the vaccine pharmaceutical composition; and
a humoral immunity induction-promoting composition comprising a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug, wherein the humoral immunity induction promoter is present in an amount of 0.001 to 10,000 parts by weight based on 1 part by weight of the antigen;
wherein the infectious pathogen is selected from adenovirus, herpesvirus, picornavirus, poxvirus, picornavirus, orthomyxovirus, paramyxovirus, parvovirus, togavirus, coronavirus, hepadnavirus, flavivirus, hepevirus, papillomavirus, calicivirus, rhabdovirus, filovirus, arenavirus, bunyavirus, reovirus, retrovirus, Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococci, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campyrobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, Bordetella, and pathogens that cause chlamydia, candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and Trypanosoma infection; and
wherein the thrombosis treatment drug is a thrombogenesis-suppressing compound that is at least one of an anticoagulant or an antiplatelet,
the anticoagulant being at least one selected from the group consisting of fondaparinux, rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, ximelagatran, dabigatran, argatroban, hirudin, nafamostat, camostat, gabexate, and warfarin, and
the antiplatelet being at least one selected from the group consisting of abciximab, eptifibatide, and tirofiban.

2. The vaccine pharmaceutical composition according to claim 1 , wherein the composition is formulated to be administered to a body surface.

3. The vaccine pharmaceutical composition according to claim 1 , wherein the composition is formulated to be administered by intradermal injection, subcutaneous injection, or intramuscular injection.

4. The vaccine pharmaceutical composition according to claim 1 , wherein the infectious pathogen is influenza.

5. The vaccine pharmaceutical composition according to claim 1 , wherein the infectious pathogen-derived antigen is selected from H1N1, H3N2, Influenza B virus, Influenza B virus, pneumococcal capsular polysaccharide, HPV16 recombinant protein, live attenuated rotavirus, inactivated poliovirus, inactivated hepatitis A virus, inactivated Japanese encephalitis virus, live attenuated mumps virus, live attenuated measles virus, live attenuated rubella virus, tetanus toxoid-conjugated haemophilus influenzae type b polysaccharide, recombinant HBs antigen protein, live attenuated yellow fever virus, tetanus toxoid, live attenuated varicella virus, live BCG, and inactivated rabies virus.

6. The vaccine pharmaceutical composition according to claim 5 , wherein the thrombosis treatment drug is selected from argatroban, nafamostat mesylate, camostat mesylate, and tirofiban.

7. A vaccine pharmaceutical composition for inducing humoral immunity, comprising:
an infectious pathogen-derived antigen; and
a humoral immunity induction-promoting composition comprising argatroban.

Assignees

• Nitto Denko Corp

Inventors

• Shishido takuya
• Asari Daisuke
• Matsushita Kyohei
• Hori Mitsuhiko

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61K2039/55588

  Adjuvants of undefined constitution · CPC title

• A61K45/00

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title